echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Multiple myeloma: 20 domestic 9 kinds of drugs listed in 1959-2017 enter the clinical practice

    Multiple myeloma: 20 domestic 9 kinds of drugs listed in 1959-2017 enter the clinical practice

    • Last Update: 2018-11-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Multiple myeloma (MM) is a malignant clonal disease characterized by abnormal proliferation of bone marrow plasma cells Only 25% of patients have chemotherapy after 5 years In hematological malignancies, the incidence rate is second only to non Hodgkin's lymphoma It is the third most common hematologic malignancy The number of new cases is 114 worldwide 000 cases; from 1959 to 2017, 20 drugs for multiple myeloma have been launched, mainly focusing on protease inhibitors and immunomodulators These new treatments have greatly improved the survival rate of MM patients However, it is worth noting that most of MM patients will still have relapse after many times of treatment, so more safe and effective drugs are still urgently needed in clinical practice! 1 Although cyclophosphamide, which was born in 1959, has been used in the treatment of multiple myeloma, three immunomodulators of Xinji company, thalidomide (thalidomide , lenalidomide (the market leader of small molecular medicine) and palmatidomine (the new generation product) have made great contributions to the treatment of multiple myeloma With the further development of immunotherapy, daratumumab, a monoclonal antibody developed by Janssen company for CD38, has further introduced the research and development direction into the current hot field Today, 20 drugs for multiple myeloma have been successfully launched in the world, and hundreds of drugs entering the development stage are in the clinical stage, with clear product development echelon 2 Introduction of representative drugs Once "thalidomide".. Angiogenesis inhibitor, which can inhibit tumor angiogenesis, and then inhibit tumor growth and metastasis, is used in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma (mm); it was approved by the US FDA in July 1998 and sold in the US by Xinji, with the trade name of thalomid ®; in 2017, the global sales volume was 132 million US dollars Lenalidomide (the second generation) thalidomide analog; in multiple myeloma cells, lenalidomide and dexamethasone can inhibit cell proliferation, leading to tumor cell apoptosis; it was approved by FDA in December 2005 and PMDA in Japan on June 25, 2010 It is listed and sold by Xinji company in the above-mentioned places, under the trade name of Revlimid ® In 2017, the global sales volume was 8.187 billion US dollars, which was the leading sales volume of small molecular drugs Pomadolamine (third generation) Thalidomide analogues can inhibit the proliferation of lenalidomide resistant multiple myeloma cell lines, and induce the apoptosis of lenalidomide sensitive and lenalidomide resistant tumor cell lines by synergism with dexamethasone The previous treatment plans for adult patients, including lenalidomide and bortezomib, have been confirmed after the last treatment For the treatment of relapsed and refractory multiple myeloma with deteriorating condition, it was approved by the FDA of the United States in 2013 and sold by Xinji company under the trade name of pomalyst (U.S.) or imnovid (Europe); in 2017, the global sales volume was US $1.614 billion Chryson & daratumab daratumab is an anti-CD38 monoclonal antibody, which can combine with CD38 on multiple myeloma cells and activate the immune system to kill tumor cells The approved indications of this drug are multiple myeloma that have been treated more than three times It was initially developed by genmab company, and then authorized to Janssen In 2015, it was approved by FDA of the United States, approved by EMA of Europe in 2016, approved by PMDA of Japan in 2017, and sold by Janssen in the United States, Europe and Japan The product name is darzalex ® In 2017, the global sales of this variety was $1.242 billion 3 11 domestic varieties enter clinical practice Although the number and status of the development of multiple myeloma drugs in China are less than that of lung cancer, breast cancer, liver cancer, etc., they are also in progress step by step Among them, 2 products have entered the clinical phase 3, 4 products have entered the clinical phase 2, and 3 products have entered the clinical phase 1 Some well-known domestic companies, such as Nanjing legend biology, Hutchison Huangpu medicine, Chengdu leader, etc., are all involved Hunting; see the table below for details.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.